Zepbound® KwikPen (tirzepatide)

Zepbound® KwikPen (tirzepatide) is a prescription once-weekly, multi-dose injectable pen designed for chronic weight management in adults with obesity, or who are overweight with at least one weight-related medical condition, when used alongside a reduced-calorie diet and increased physical activity. It contains the same active ingredient as Zepbound single-dose pens but is supplied in a convenient multi-dose KwikPen format, allowing multiple weekly doses from a single pen.

Available Strengths

• 2.5 mg
• 5 mg
• 7.5 mg
• 10 mg
• 12.5 mg
• 15 mg

Typical Dosing Schedule

• Weeks 1–4: 2.5 mg once weekly (starting dose)
• Weeks 5–8: 5 mg once weekly
• If additional weight loss is needed, the dose may be increased in 2.5 mg increments every 4 weeks:
  • 7.5 mg once weekly
  • 10 mg once weekly
  • 12.5 mg once weekly
  • 15 mg once weekly (maximum recommended dose)

Common Side Effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach pain
• Decreased appetite
• Indigestion
• Fatigue

These side effects are generally mild to moderate and often improve as your body adjusts to treatment.

Benefits

• Supports significant and sustained weight loss when combined with a reduced-calorie diet and regular physical activity.
• Helps reduce appetite and control food cravings.
• Convenient once-weekly dosing with a multi-dose KwikPen.
• Delivers the same proven tirzepatide therapy in an easy-to-use pen format.

Important Safety Information

Zepbound® KwikPen should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not recommended during pregnancy. Use the KwikPen exactly as instructed by your healthcare provider, following the prescribed dose-escalation schedule and proper injection technique.